Nathan Bennett, PA
Medical · Somerset, KYNPI 1467894089
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 202 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations.
Across 202 payments — averaging $15.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$643
- Merck$518
- Amgen$444
- Sanofi-aventis U.S. LLC$221
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$205
- Johnson & Johnson$204
- plus $942 from 20 others
What the payments were for
- Food & beverage$3,165100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 49 | $643 |
| Merck | 29 | $518 |
| Amgen | 29 | $444 |
| Sanofi-aventis U.S. LLC | 16 | $221 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $205 |
| Johnson & Johnson | 12 | $204 |
| Irhythm Technologies, Inc. | 7 | $157 |
| Boston Scientific | 6 | $141 |
| AstraZeneca | 8 | $127 |
| Boehringer Ingelheim | 5 | $88 |
| Lexicon Pharmaceuticals, Inc. | 4 | $71 |
| Pfizer | 4 | $61 |
| Novo Nordisk | 3 | $56 |
| Bayer | 2 | $36 |
| Baxter Healthcare | 1 | $31 |
| Mindray DS USA, Inc. | 1 | $29 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Abbott | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| GSK | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
| Intuitive Surgical | 1 | $8 |
How this compares
$3,176 in reported general payments places this provider in the 75th percentile of 222 medical providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 593 | $483,775 |
| EliquisApixaban | 479 | $451,183 |
| Repatha SureclickEvolocumab | 168 | $134,538 |
| FarxigaDapagliflozin Propanediol | 176 | $118,312 |
| LeqvioInclisiran Sodium | 32 | $104,699 |
| XareltoRivaroxaban | 74 | $69,198 |
| JardianceEmpagliflozin | 53 | $50,336 |
| Repatha PushtronexEvolocumab | 64 | $46,430 |
| Praluent PenAlirocumab | 59 | $41,135 |
| MultaqDronedarone Hcl | 29 | $28,900 |
| Ranolazine ErRanolazine | 272 | $28,245 |
| VerquvoVericiguat | 16 | $14,284 |
| BrilintaTicagrelor | 19 | $13,631 |
| Flecainide Acetate | 313 | $10,874 |
| Metoprolol Succinate | 607 | $3,874 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto, Leqvio | $643 | $588,474625 claims |
| PfizerEliquis | $61 | $451,183479 claims |
| AstraZenecaFarxiga, Brilinta | $127 | $131,942195 claims |
| Johnson & JohnsonXarelto | $204 | $69,19874 claims |
| Boehringer IngelheimJardiance | $88 | $50,33653 claims |
| Sanofi-aventis U.S. LLCMultaq | $221 | $28,90029 claims |
| MerckVerquvo | $518 | $14,28416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 222 medical providers in Kentucky.
Other medical in Somerset
- Mikal BaileyPaducah$84K
- Kyle HeraldBowling Green$65K
- Chasity HesterLexington$16K
- Alexandra HuettLouisville$13K
- Danny ThackerFrankfort$11K
- Jessica FrizzellPaducah$10K
- Terry SmithHazard$10K
- Ashley HenegarGeorgetown$10K
- Rachel CrowleyPaducah$8K
- Allison ScottLexington$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.